Skip to main content
. Author manuscript; available in PMC: 2019 Jun 11.
Published in final edited form as: Arthritis Rheumatol. 2017 May;69(5):986–995. doi: 10.1002/art.40035

Figure 1:

Figure 1:

RA patient plasma preferentially binds PAD4 citrullinated fibrinogen as measured by ELISA. (A) Normal donor and RA patient antibody levels, as measured by ELISA, to unmodified fibrinogen at 1:20 dilution, PAD2 citrullinated fibrinogen at 1:40 dilution and PAD4 citrullinated fibrinogen at 1:40 dilution. (B) Individual RA patient antibody levels to PAD4 citrullinated fibrinogen and PAD2 citrullinated fibrinogen at various dilutions. (C) Ratio of individual RA patient plasma binding to PAD4 or PAD2 citrullinated fibrinogen. Ratio calculated as (OD of PAD4 citrullinated fibrinogen)/(OD of PAD2 citrullinated fibrinogen) of individual patients from (B) at various dilutions. (D) Individual RA antibody levels to autocitrullinated PAD2 and PAD4 at various dilutions. Data represent 1 of 3 independent experiments. CitFib= citrullinated fibrinogen OD= optical density. *** P<0.005, ns=not significant.